ABCL Before May 11 Earnings: The AI Antibody Discovery Bag Is Finally Entering Catalyst Season - DD
# ABCL Before May 11 Earnings: The AI Antibody Discovery Bag Is Finally Entering Catalyst Season
Three years ago I posted about AbCellera as an AI-powered antibody discovery company that Wall Street was sleeping on. Back then, the bull case was mostly platform, partnerships, cash, and the hope that the COVID antibody success was proof the engine worked. The stock got smoked after that, and fair enough, because “cool platform” does not pay you unless molecules actually move toward patients[.](https://imgur.com/a/B6Ivc9C)
That is the part that has changed.
ABCL is no longer just a discovery platform story. It has now transitioned into a clinical-stage biotech with two internal programs in human trials, two more in IND/CTA-enabling work, 104 cumulative partner-initiated programs with downstream economics, and 19 cumulative molecules that have reached the clinic.
# Why May 11 Matters
The Q1 earnings call is scheduled for Monday, May 11, 2026, at 5:00 PM ET. But the earnings numbers are probably not the real event. AbCellera has already announced that it will disclose interim Phase 1 data for ABCL635 on that call, including safety, pharmacokinetics, and pharmacodynamic target engagement data.
ABCL635 is the lead program. It targets NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms from menopause, commonly known as hot flashes. AbCellera says the ongoing Phase 2 portion in postmenopausal women is expected to read out in Q3 2026.
Translation: May 11 is not just “earnings.” It is the first real look at whether ABCL’s internal pipeline has legs.
# What Changed Since My Original DD
The old ABCL thesis was: great tech, big partners, lots of cash, and maybe the market forgot how valuable antibody discovery can be.
The updated thesis is: the platform has matured into an actual pipeline.
AbCellera ended 2025 with $75.1 million in revenue, a net loss of $146.4 million, and approximately $700 million in available liquidity when including cash, marketable securities, and available non-dilutive government funding. Management says that liquidity is enough to fund the strategy well beyond the next three years of pipeline investment.
That matters because small-cap biotech usually dies by dilution. ABCL still burns money, but it is not some broke science project begging the market for survival capital every six months.
# Pipeline Setup
Current internal pipeline snapshot:
ABCL635: NK3R antibody for menopause-related hot flashes. Phase 1/2. Interim Phase 1 data May 11. Phase 2 readout expected Q3 2026.
ABCL575: OX40L antibody for moderate-to-severe atopic dermatitis, with potential use in other inflammatory and autoimmune conditions. Phase 1 data expected mid-2026.
ABCL688: undisclosed GPCR or ion channel target in autoimmunity, now in IND/CTA-enabling activities.
ABCL386: undisclosed oncology program, also in IND/CTA-enabling activities.
So the question is no longer “can this company discover antibodies?” The question is “can this company turn its platform into valuable clinical assets?”
# Stock Setup
ABCL is trading around $4.80 today with a market cap around $1.43 billion.
Analyst expectations for Q1 are not huge: MarketBeat shows consensus estimates around a $0.22 loss per share and about $5.7 million in revenue. But again, the revenue number is not the main event. The May 11 call is about ABCL635 data and what management says about the 2026 catalyst path.
Recent analyst commentary has also warmed up. MarketBeat shows a moderate buy consensus with an average target around $8.17, while recent coverage included an $11 target.
# My Position
I am holding 8,000 shares with a $4.25 average.
https://preview.redd.it/nv3mo59u4czg1.png?width=1320&format=png&auto=webp&s=035fe15de331f22418c9798fc0494697ae04ccc6
At roughly $4.80, that position is worth about $38,360. A 10x from here would imply roughly $48 per share and a position value around $383,600.
That is obviously not my base case for next week. A 10x would require clinical success, pipeline validation, probably partnerships or commercial optionality, and the market deciding ABCL deserves to be valued like a serious platform biotech instead of a forgotten post-COVID SPAC corpse.
# Bull Case
ABCL has a real platform, real cash, real facilities, real partner economics, and now real internal clinical programs. The company spent years building the machine, and 2026 is the year investors finally get data showing whether the machine can create valuable drugs.
If ABCL635 shows clean safety, strong target engagement, and a believable path toward differentiated dosing, the stock could re-rate before the Q3 Phase 2 readout.
If ABCL575 also hits later this year, ABCL starts looking less like a one-asset biotech and more like a repeatable antibody engine.
# Bear Case
This is still biotech. Cash does not matter if the drugs do not work.
ABCL635 could show weak target engagement, safety concerns, unimpressive PK, or nothing that proves it can compete. Revenue is still lumpy, operating losses remain meaningful, and the company is not close to commercial sales from its internal pipeline. FY2025 revenue also included a large patent-litigation settlement component, so investors should not treat that revenue level as clean recurring growth.
This can absolutely go down hard if the May 11 data disappoints.
# What I’m Watching On May 11
The key items:
1. ABCL635 safety profile
2. ABCL635 pharmacokinetics and dosing potential
3. Pharmacodynamic target engagement
4. Whether management sounds confident on Q3 Phase 2 timing
5. Cash burn and runway
6. Updates on ABCL575, ABCL688, and ABCL386
7. Any new partner program movement or molecule-in-clinic updates
# Bottom Line
My original DD was early. Maybe way too early.
But the 2026 setup is much stronger than the 2023 setup. ABCL has moved from “interesting AI antibody platform with cash” to “clinical-stage biotech with multiple internal shots on goal, partner optionality, and a major data catalyst on deck.”
May 11 is the first real test.
Still holding. Not financial advice. Biotech can vaporize your face.